Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
about
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsA novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growthMyosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motilityMaximizing the Therapeutic Potential of HSP90 InhibitorsDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsDrugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressA phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsRegulation and function of the human HSP90AA1 geneThe HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageHeat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.Guidelines for the welfare and use of animals in cancer research.Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinRadiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1αEffects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance SpectroscopyA first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2Withaferin A targets heat shock protein 90 in pancreatic cancer cells.Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PETTargeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerHsp90 molecular chaperone inhibitors: are we there yet?Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation.Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapyCombined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cellsTargeting chaperones in transformed systems--a focus on Hsp90 and cancer.Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trialsNew approaches to molecular cancer therapeutics.Heat shock proteins and regulatory T cellsInhibitors of the heat shock response: biology and pharmacology.A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.Network analysis identifies an HSP90-central hub susceptible in ovarian cancerHeat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells.KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cellsTargeting HSP90 for cancer therapy.Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
P2860
Q21195221-4ED8A8EC-C714-45FD-A815-F40619B6F556Q24309277-FF4FB520-FF8D-4BA8-A669-D249C0DE3231Q24672758-FAF00A30-7930-4F26-8363-FE702F88F990Q26798318-9A2B6348-3064-49F9-AF69-814ADBED3DA2Q28254233-84A4F977-C10B-41BD-939B-BA8509C9F363Q28303213-A43290C9-F21F-4F29-94FA-0510986F4A92Q28304273-BC864877-964E-4211-89AD-95A1CCFE273BQ28646043-C03F287D-FB11-435A-9FF2-20691FCDE0B3Q28730558-5E2C3ED4-0E8C-408B-B381-D43FFC7CEEDCQ30585904-08B3D801-5FAB-4457-B22E-3B645AF826DAQ33903753-D12D025E-7311-41EA-8BE9-2A386EF5A9A0Q34018372-37ED44A6-7CBD-4C9C-856D-8C2E2F35E544Q34162720-E37F0FA8-6648-447C-A55B-71065D4675C1Q34278997-C1DFE86F-2B4F-494F-B592-954E027D1701Q34636437-60249C2A-DED6-4D6B-B39B-45404D41C0DAQ34989144-8579C4EE-B7D5-4566-A087-DBE1DF3106AEQ35004306-966656F0-F09A-44B8-983B-CA47A66D0F4FQ35350578-5BEA116D-C320-4071-8A17-20506A6AE08EQ35390011-06932502-883E-4F77-A8B2-3642E040F7EAQ35469572-A31D99BA-02EB-4E2D-97F3-E730B2BC903CQ35655105-139A39F9-AFD6-4548-96A1-14E6B3EA088DQ35676153-B4160CA9-2859-40F9-8A25-BCC060952095Q35760817-78C01FDE-7A0A-4710-A267-8355932E169EQ35775241-7F2657DC-F725-4317-8400-AD6410DDF90BQ36103054-B64863CA-0B61-49CC-83B8-DC2D53F9978CQ36338764-FFA607FD-080D-4E43-8468-FF77455A4C80Q36379365-A91ED090-3E6F-43BA-9300-4E9DB5A64EA1Q36472987-5D9B34DB-7D85-4DA7-B8C5-9B7F600476BCQ36493048-5910873F-98F1-483F-8B7F-EFE83509B1F0Q36654909-A4359A85-566E-478C-A3E9-FDDE7D1347FAQ36729007-C933BA2E-0265-47C6-BEB6-648CEB5CF2B1Q36845355-34BA56B4-EF90-4790-ABF2-7E79848B5609Q36976738-DB6C77DC-3BEE-46EE-AEE1-2D19DC22E183Q37185385-A2746AD8-72E5-4269-B12A-3E4B0A022BCDQ37198085-1F89F2C4-1D05-4DB4-99C7-3EB5A586C9B8Q37369580-29BE164D-87E7-4B2A-A905-DD95813C5D19Q37397036-D0477E3E-D169-4A8C-9280-01AE0E229D79Q37444497-57315BFB-1B2F-42F6-9161-AE7C21090E95Q37463739-E896DB95-652A-4DC9-9E28-8DB43106A774Q37702589-3260D5CC-B3D9-40CB-BCDE-C1F10D5E7A6C
P2860
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@ast
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en-gb
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@nl
type
label
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@ast
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en-gb
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@nl
prefLabel
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@ast
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en-gb
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@nl
P2093
P921
P3181
P1476
Pharmacokinetic-pharmacodynami ...... varian cancer xenograft models
@en
P2093
Florence Raynaud
Ian Judson
Lloyd Kelland
Melani Valenti
Michael Walton
Rachel Grimshaw
P304
P3181
P356
10.1158/1078-0432.CCR-05-0518
P407
P433
P577
2005-10-01T00:00:00Z